Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) and Candel Therapeutics (NASDAQ:CADL – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Institutional & Insider Ownership
43.3% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.1% of Candel Therapeutics shares are owned by institutional investors. 9.4% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 44.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Get
Fennec Pharmaceuticals alerts:
Volatility and Risk
Fennec Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Profitability
This table compares Fennec Pharmaceuticals and Candel Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Fennec Pharmaceuticals | N/A | -214.78% | -97.25% |
| Candel Therapeutics | N/A | -20.18% | -13.13% |
Valuation and Earnings
This table compares Fennec Pharmaceuticals and Candel Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Fennec Pharmaceuticals | $170,000.00 | 1,483.88 | -$17.35 million | ($0.82) | -11.71 |
| Candel Therapeutics | $130,000.00 | 397.85 | -$36.12 million | ($0.42) | -4.26 |
Fennec Pharmaceuticals has higher revenue and earnings than Candel Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Fennec Pharmaceuticals and Candel Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Fennec Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| Candel Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Fennec Pharmaceuticals presently has a consensus price target of $14.83, indicating a potential upside of 54.51%. Candel Therapeutics has a consensus price target of $10.33, indicating a potential upside of 477.28%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Fennec Pharmaceuticals.
Summary
Candel Therapeutics beats Fennec Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Fennec Pharmaceuticals
(Get Rating)
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
About Candel Therapeutics
(Get Rating)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
